Anti-neoplastic drugs US Medical PG Practice Questions and MCQs
Practice US Medical PG questions for Anti-neoplastic drugs. These multiple choice questions (MCQs) cover important concepts and help you prepare for your exams.
Anti-neoplastic drugs US Medical PG Question 1: A research team develops a new monoclonal antibody checkpoint inhibitor for advanced melanoma that has shown promise in animal studies as well as high efficacy and low toxicity in early phase human clinical trials. The research team would now like to compare this drug to existing standard of care immunotherapy for advanced melanoma. The research team decides to conduct a non-randomized study where the novel drug will be offered to patients who are deemed to be at risk for toxicity with the current standard of care immunotherapy, while patients without such risk factors will receive the standard treatment. Which of the following best describes the level of evidence that this study can offer?
- A. Level 1
- B. Level 3 (Correct Answer)
- C. Level 5
- D. Level 4
- E. Level 2
Anti-neoplastic drugs Explanation: ***Level 3***
- A **non-randomized controlled trial** like the one described, where patient assignment to treatment groups is based on specific characteristics (risk of toxicity), falls into Level 3 evidence.
- This level typically includes **non-randomized controlled trials** and **well-designed cohort studies** with comparison groups, which are prone to selection bias and confounding.
- The study compares two treatments but lacks randomization, making it Level 3 evidence.
*Level 1*
- Level 1 evidence is the **highest level of evidence**, derived from **systematic reviews and meta-analyses** of multiple well-designed randomized controlled trials or large, high-quality randomized controlled trials.
- The described study is explicitly stated as non-randomized, ruling out Level 1.
*Level 2*
- Level 2 evidence involves at least one **well-designed randomized controlled trial** (RCT) or **systematic reviews** of randomized trials.
- The current study is *non-randomized*, which means it cannot be classified as Level 2 evidence, as randomization is a key criterion for this level.
*Level 4*
- Level 4 evidence includes **case series**, **case-control studies**, and **poorly designed cohort or case-control studies**.
- While the study is non-randomized, it is a controlled comparative trial rather than a case series or retrospective case-control study, placing it at Level 3.
*Level 5*
- Level 5 evidence is the **lowest level of evidence**, typically consisting of **expert opinion** without explicit critical appraisal, or based on physiology, bench research, or animal studies.
- While the drug was initially tested in animal studies, the current human comparative study offers a higher level of evidence than expert opinion or preclinical data.
Anti-neoplastic drugs US Medical PG Question 2: A 55-year-old Caucasian male presents for a routine colonoscopy. A polyp is found in the patient's transverse colon and is found to be cancerous on histological evaluation. Upon examination, it is found that these cancerous cells have decreased MHC class I expression on their surface. Which immune system cell is most capable of killing these tumor cells?
- A. Cytotoxic T-cells
- B. B-cells
- C. Macrophages
- D. Natural killer cells (Correct Answer)
- E. Eosinophils
Anti-neoplastic drugs Explanation: ***Natural killer cells***
- **Natural killer (NK) cells** are specialized lymphocytes that identify and kill cells with **decreased or absent MHC class I expression**, a common feature of tumor cells and virus-infected cells.
- They provide a rapid, non-specific immune response without prior sensitization.
*Cytotoxic T-cells*
- **Cytotoxic T-cells (CTLs)** recognize and kill target cells by binding to specific **antigens presented by MHC class I molecules**.
- Since these cancer cells have **decreased MHC class I expression**, CTLs would be less effective at recognizing and killing them.
*B-cells*
- **B-cells** are primarily involved in humoral immunity, producing **antibodies** that can neutralize pathogens or mark cells for destruction.
- They do not directly kill target cells, and their activation typically requires specific antigen recognition, often with T-cell help.
*Macrophages*
- **Macrophages** are phagocytic cells that engulf and digest cellular debris, pathogens, and some tumor cells.
- While they can kill tumor cells, their primary mechanism involves **phagocytosis** or antigen presentation, not direct cytotoxicity based on MHC I expression levels.
*Eosinophils*
- **Eosinophils** are granulocytes primarily involved in the defense against **parasitic infections** and in allergic reactions.
- They are not a primary defense mechanism against tumor cells, especially not based on MHC class I expression.
Anti-neoplastic drugs US Medical PG Question 3: A 60-year-old female presents to her gynecologist with bloating, abdominal discomfort, and fatigue. She has a history of hypertension and takes hydrochlorothiazide. Physical exam reveals ascites and right adnexal tenderness. Initial imaging reveals a mass in the right ovary and eventual biopsy of the mass reveals ovarian serous cystadenocarcinoma. She is started on a chemotherapeutic agent with plans for surgical resection. Soon after starting the medication, she develops dysuria and hematuria. Laboratory analysis of her urine is notable for the presence of a cytotoxic metabolite. Which of the following mechanisms of action is consistent with the medication in question?
- A. Folate analog
- B. Microtubule inhibitor
- C. DNA alkylating agent (Correct Answer)
- D. Platinum-based DNA cross-linking agent
- E. BRAF inhibitor
Anti-neoplastic drugs Explanation: ***DNA alkylating agent***
- Cyclophosphamide is a **DNA alkylating agent** commonly used in the treatment of ovarian cancer. It is metabolized to **acrolein**, a cytotoxic metabolite that causes **hemorrhagic cystitis**, presenting as dysuria and hematuria.
- DNA alkylating agents exert their cytotoxic effects by forming **covalent bonds** with DNA, leading to DNA damage, cross-linking, and subsequent inhibition of DNA replication and transcription, ultimately inducing **apoptosis** in rapidly dividing cancer cells.
*Folate analog*
- Folate analogs like **methotrexate** inhibit **dihydrofolate reductase**, interfering with DNA synthesis by depleting tetrahydrofolate, a crucial cofactor for nucleotide synthesis.
- While they are chemotherapeutic agents, they do not typically cause hemorrhagic cystitis; their common side effects include **myelosuppression**, mucositis, and hepatotoxicity.
*Microtubule inhibitor*
- Microtubule inhibitors such as **paclitaxel** and **vincristine** interfere with microtubule formation or breakdown, disrupting cell division (mitosis).
- Common side effects include **neuropathy** and myelosuppression, but not hemorrhagic cystitis.
*Platinum-based DNA cross-linking agent*
- Platinum-based drugs like **cisplatin** and **carboplatin** are often used for ovarian cancer and cause nephrotoxicity, neurotoxicity, and ototoxicity.
- They form **DNA adducts and interstrand cross-links**, inhibiting DNA replication and transcription, but do not directly cause acrolein-induced hemorrhagic cystitis.
*BRAF inhibitor*
- BRAF inhibitors (e.g., **vemurafenib**) are **targeted therapies** used in cancers with specific mutations, such as BRAF-mutated melanoma.
- They inhibit the BRAF kinase in the MAPK signaling pathway, and while effective in specific contexts, they are not typically associated with hemorrhagic cystitis.
Anti-neoplastic drugs US Medical PG Question 4: A 62-year-old woman presents to her oncologist to discuss the chemotherapy options for her newly diagnosed breast cancer. During the meeting, they discuss a drug that inhibits the breakdown of mitotic spindles in cells. Her oncologist explains that this will be more toxic to cancer cells because those cells are dividing more rapidly. Which of the following side effects is closely associated with the use of this chemotherapeutic agent?
- A. Photosensitivity
- B. Peripheral neuropathy (Correct Answer)
- C. Paralytic ileus
- D. Hemorrhagic cystitis
- E. Pulmonary fibrosis
Anti-neoplastic drugs Explanation: ***Peripheral neuropathy***
- Drugs that inhibit the breakdown of **mitotic spindles** are **microtubule-targeting agents** (e.g., **taxanes** like paclitaxel/docetaxel, **vinca alkaloids** like vincristine/vinblastine).
- These agents interfere with **microtubule function** in neurons, leading to **axonal damage** and **peripheral neuropathy**.
- This is the **most characteristic and common dose-limiting toxicity** of microtubule inhibitors, affecting sensory and motor nerves (numbness, tingling, weakness in extremities).
*Photosensitivity*
- **Photosensitivity** is a common adverse effect associated with certain chemotherapeutic agents like **fluorouracil** (5-FU) or **methotrexate**, but is not linked to microtubule inhibitors.
- It involves an increased sensitivity to UV light, often manifesting as a rash or exaggerated sunburn.
*Paralytic ileus*
- **Paralytic ileus** can occur with **vinca alkaloids** (especially vincristine) due to autonomic neuropathy affecting the **enteric nervous system**.
- However, this is **less common** than peripheral neuropathy and occurs more specifically with vincristine rather than taxanes.
- **Peripheral neuropathy** is the more pervasive, dose-limiting, and universally characteristic side effect across all microtubule inhibitors.
*Hemorrhagic cystitis*
- **Hemorrhagic cystitis** is a classic side effect of **alkylating agents** like **cyclophosphamide** and **ifosfamide**, which produce the toxic metabolite **acrolein**.
- It is prevented/managed with **mesna**, which inactivates acrolein.
- Not associated with microtubule inhibitors.
*Pulmonary fibrosis*
- **Pulmonary fibrosis** is a known side effect of certain chemotherapeutic drugs, most notably **bleomycin** and **busulfan**.
- This adverse effect is not associated with agents that target **mitotic spindle breakdown**.
Anti-neoplastic drugs US Medical PG Question 5: A 57-year-old man presents to his oncologist to discuss management of small cell lung cancer. The patient is a lifelong smoker and was diagnosed with cancer 1 week ago. The patient states that the cancer was his fault for smoking and that there is "no hope now." He seems disinterested in discussing the treatment options and making a plan for treatment and followup. The patient says "he does not want any treatment" for his condition. Which of the following is the most appropriate response from the physician?
- A. "You seem upset at the news of this diagnosis. I want you to go home and discuss this with your loved ones and come back when you feel ready to make a plan together for your care."
- B. "It must be tough having received this diagnosis; however, new cancer therapies show increased efficacy and excellent outcomes."
- C. "It must be very challenging having received this diagnosis. I want to work with you to create a plan." (Correct Answer)
- D. "We are going to need to treat your lung cancer. I am here to help you throughout the process."
- E. "I respect your decision and we will not administer any treatment. Let me know if I can help in any way."
Anti-neoplastic drugs Explanation: ***"It must be very challenging having received this diagnosis. I want to work with you to create a plan."***
- This response **acknowledges the patient's emotional distress** and feelings of guilt and hopelessness, which is crucial for building rapport and trust.
- It also gently **re-engages the patient** by offering a collaborative approach to treatment, demonstrating the physician's commitment to supporting him through the process.
*"You seem upset at the news of this diagnosis. I want you to go home and discuss this with your loved ones and come back when you feel ready to make a plan together for your care."*
- While acknowledging distress, sending the patient home without further engagement **delays urgent care** for small cell lung cancer, which is aggressive.
- This response might be perceived as dismissive of his immediate feelings and can **exacerbate his sense of hopelessness** and isolation.
*"It must be tough having received this diagnosis; however, new cancer therapies show increased efficacy and excellent outcomes."*
- This statement moves too quickly to treatment efficacy without adequately addressing the patient's current **emotional state and fatalism**.
- While factual, it **lacks empathy** for his personal feelings of blame and hopelessness, potentially making him feel unheard.
*"We are going to need to treat your lung cancer. I am here to help you throughout the process."*
- This response is **too directive and authoritarian**, which can alienate a patient who is already feeling guilty and resistant to treatment.
- It fails to acknowledge his stated feelings of "no hope now" or his disinterest in treatment, which are critical to address before discussing the necessity of treatment.
*"I respect your decision and we will not administer any treatment. Let me know if I can help in any way."*
- While respecting patient autonomy is vital, immediately accepting a patient's decision to refuse treatment without exploring the underlying reasons (e.g., guilt, hopelessness, lack of information) is **premature and potentially harmful**.
- The physician has a responsibility to ensure the patient is making an informed decision, especially for a rapidly progressing condition like small cell lung cancer.
More Anti-neoplastic drugs US Medical PG questions available in the OnCourse app. Practice MCQs, flashcards, and get detailed explanations.
